| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Nemours Children’s Clinic and Research Programs (N.M.), Jacksonville, Florida 32207; Baystate Medical Center (E.O.R.), Springfield, Massachusetts 01199; Montefiore Medical Center (P.S.), Bronx, New York 10467; and Genentech, Inc. (K.M.A., J.B.), South San Francisco, California 94080
Address all correspondence and requests for reprints to: Nelly Mauras, M.D., Division of Endocrinology, Nemours Children’s Clinic, 807 Nira Street, Jacksonville, Florida 32211. E-mail: nmauras{at}nemours.org
GH production rates markedly increase during human puberty, mostly as an amplitude-modulated phenomenon. However, GH-deficient children have been dosed on a standard per kg BW basis similar to prepubertal children. This randomized study was designed to compare the efficacy and safety of standard recombinant human GH (rhGH) therapy (group I, 0.3 mg/kg·week) vs. high dose therapy (group II, 0.7 mg/kg·week) in GH-deficient adolescents previously treated with rhGH for at least 6 months. Ninety-seven children with documented evidence of GH deficiency (peak GH in response to stimuli, <10 ng/mL), with either organic or idiopathic pathology, were recruited. Both groups were matched for sex (group I, 42 males and 7 females; group II, 41 males and 7 females), age [group I, 14.0 ± 1.6 (±SD) yr; group II, 13.7 ± 1.6], standardized height (group I, -1.4 ± 1.1; group II, -1.2 ± 1.1), bone age (group I, 13.1 ± 1.3 yr; group II, 13.1 ± 1.3) etiology, maximum stimulated GH, previous growth rate, and midparental target height. All subjects were in puberty (Tanner stage 2–5) at study entry.
Of the 97 subjects enrolled, 45 were treated for 3 yr or more; 48 completed the study. Of the subjects who discontinued the study, the most common reason was satisfaction with their height, although others discontinued for adverse events or personal reasons. The frequency of patients who discontinued was the same in both groups. The primary efficacy analysis was the difference between dose groups for near-adult height, defined as the height attained at a bone age of 16 yr or more in males and 14 yr or more in girls; all subjects who qualified were included in the analysis. This difference was statistically significant at 4.6 cm by analysis of covariance (ANCOVA; P < 0.001; n = 75). For subjects who received at least 4 yr of rhGH treatment, the difference between dose groups at that time point was 5.7 cm (by ANCOVA, P = 0.024; n = 20). The mean height SD score at near-adult height was -0.7 ± 0.9 in the standard dose group and 0.0 ± 1.2 in the high dose group. At 36 months the cumulative change in height (centimeters) was 21.5 ± 5.3 cm (group I) vs. 25.1 ± 4.9 (group II; P < 0.001, by ANCOVA); the change in Bayley-Pinneau predicted adult height was 4.8 ± 4.2 cm (group I) vs. 8.4 ± 5.7 (group II; P = 0.032). Median plasma IGF-I concentrations at baseline were 427 µg/L (range, 204–649) in group I and 435 µg/L (range, 104–837) in group II; at 36 months they were 651 µg/L (range, 139-1079) in group I vs. 910 µg/L (range, 251-1843) in group II (P = NS). No difference in change in bone age was detected between groups at any interval. High dose rhGH was well tolerated, with a similar safety profile as standard dose treatment and no difference in hemoglobin A1c or glucose concentrations between groups.
In summary, compared to conventional treatment, high dose rhGH therapy in adolescents 1) increased near-adult height and height SD scores significantly, 2) did not increase the rate of skeletal maturation, and 3) appears to be well tolerated and safe. In conclusion, high dose rhGH therapy may have a beneficial effect in adolescent GH-deficient patients, particularly those who are most growth retarded at the start of puberty.
This article has been cited by other articles:
 |
|
 |
|
  N. Mauras, L. Gonzalez de Pijem, H. Y. Hsiang, P. Desrosiers, R. Rapaport, I. D. Schwartz, K. O. Klein, R. J. Singh, A. Miyamoto, and K. Bishop Anastrozole Increases Predicted Adult Height of Short Adolescent Males Treated with Growth Hormone: A Randomized, Placebo-Controlled, Multicenter Trial for One to Three Years J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 823 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Cohen, A. D. Rogol, C. P. Howard, G. M. Bright, A.-M. Kappelgaard, R. G. Rosenfeld, and on behalf of the American Norditropin Study Group Insulin Growth Factor-Based Dosing of Growth Hormone Therapy in Children: A Randomized, Controlled Study J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2480 - 2486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Hardin, S. F. Kemp, and D. B. Allen Twenty Years of Recombinant Human Growth Hormone in Children: Relevance to Pediatric Care Providers Clinical Pediatrics, May 1, 2007; 46(4): 279 - 286. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Saenger, P. Czernichow, I. Hughes, and E. O. Reiter Small for Gestational Age: Short Stature and Beyond Endocr. Rev., April 1, 2007; 28(2): 219 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Ali, M. Shim, E. Fowler, M. Greenberg, D. Perkins, W. Oppenheim, and P. Cohen Growth Hormone Therapy Improves Bone Mineral Density in Children with Cerebral Palsy: A Preliminary Pilot Study J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 932 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zucchini, P. Pirazzoli, F. Baronio, M. Gennari, M. O. Bal, A. Balsamo, S. Gualandi, and A. Cicognani Effect on Adult Height of Pubertal Growth Hormone Retesting and Withdrawal of Therapy in Patients with Previously Diagnosed Growth Hormone Deficiency J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4271 - 4276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Allen Growth Hormone Therapy for Short Stature: Is the Benefit Worth the Burden? Pediatrics, July 1, 2006; 118(1): 343 - 348. [Full Text] [PDF]
|
|
|
|
|
|
E. O. Reiter, D. A. Price, P. Wilton, K. Albertsson-Wikland, and M. B. Ranke Effect of Growth Hormone (GH) Treatment on the Near-Final Height of 1258 Patients with Idiopathic GH Deficiency: Analysis of a Large International Database J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2047 - 2054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Lee, M. M. Davis, S. J. Clark, T. P. Hofer, and A. R. Kemper Estimated Cost-effectiveness of Growth Hormone Therapy for Idiopathic Short Stature Arch Pediatr Adolesc Med, March 1, 2006; 160(3): 263 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers Endocrine Control of Body Composition in Infancy, Childhood, and Puberty Endocr. Rev., February 1, 2005; 26(1): 114 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. W. Leschek, S. R. Rose, J. A. Yanovski, J. F. Troendle, C. A. Quigley, J. J. Chipman, B. J. Crowe, J. L. Ross, F. G. Cassorla, W. F. Blum, et al. Effect of Growth Hormone Treatment on Adult Height in Peripubertal Children with Idiopathic Short Stature: A Randomized, Double-Blind, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3140 - 3148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Underwood, K. M. Attie, and J. Baptista Growth Hormone (GH) Dose-Response in Young Adults with Childhood-Onset GH Deficiency: A Two-Year, Multicenter, Multiple-Dose, Placebo-Controlled Study J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5273 - 5280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Xu, A. Janss, and T. Moshang Adult Height and Adult Sitting Height in Childhood Medulloblastoma Survivors J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4677 - 4681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Ranke, A. Lindberg, D. D. Martin, B. Bakker, P. Wilton, K. Albertsson-Wikland, C. T. Cowell, D. A. Price, and E. O. Reiter The Mathematical Model for Total Pubertal Growth in Idiopathic Growth Hormone (GH) Deficiency Suggests a Moderate Role of GH Dose J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4748 - 4753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tauber, B. Berro, V. Delagnes, N. Lounis, B. Jouret, C. Pienkowski, I. Oliver, and P. Rochiccioli Can Some Growth Hormone (GH)-Deficient Children Benefit from Combined Therapy with Gonadotropin-Releasing Hormone Analogs and GH? Results of a Retrospective Study J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1179 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Carel, E. Ecosse, J. Coste, S. Loche, M. Maghnie, and M. Cappa Growth hormone in growth hormone deficiency BMJ, November 2, 2002; 325(7371): 1037 - 1037. [Full Text]
|
|
|
|
|
|
V. Mericq, H. Gajardo, M. Eggers, A. Avila, and F. Cassorla Effects of Treatment with GH Alone or in Combination with LHRH Analog on Bone Mineral Density in Pubertal GH-Deficient Patients J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 84 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Cohen, G. M. Bright, A. D. Rogol, A.-M. Kappelgaard, and R. G. Rosenfeld Effects of Dose and Gender on the Growth and Growth Factor Response to GH in GH-Deficient Children: Implications for Efficacy and Safety J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 90 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O. Reiter, S. L. Blethen, J. Baptista, and L. Price Early Initiation of Growth Hormone Treatment Allows Age-Appropriate Estrogen Use in Turner's Syndrome J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1936 - 1941. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
